Ivan Cuccovillo

Ivan Cuccovillo

Auto-generated profile, based on publicly available information

Ivan Cuccovillo

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2010 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
LDLivija Deban
Livija Deban
Remo C. RussoRemo C. Russo
Remo C. Russo
MSMarina Sironi
Marina Sironi
FMFederica Moalli
Federica Moalli
MSMargherita Scanziani
Margherita Scanziani
Alberto MantovaniAlberto Mantovani
Alberto Mantovani

11 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
STSimone Torretta
Simone Torretta
ASAlessandra Scagliola
Alessandra Scagliola
LRLuisa Ricci
Luisa Ricci
francesco maininifrancesco mainini
francesco mainini
SMSabrina Di Marco
Sabrina Di Marco
SCSimone Cardaci
Simone Cardaci
D-mannose is a monosaccharide approximately a hundred times less abundant than glucose in human blood. Previous studies demonstrated that supraphysiological levels of D-mannose inhibit tumour growth and stimulate regulatory T cell differentiation. It is not known whether D-mannose metabolism affects the function of non-proliferative cells, such as inflammatory macrophages. Here, we show that D-mannose suppresses LPS-induced macrophage activation by impairing IL-1β production. In vivo, mannose administration improves survival in a mouse model of LPS-induced endotoxemia as well as decreases progression in a mouse model of DSS-induced colitis. Phosphomannose isomerase controls response of LPS-activated macrophages to D-mannose, which impairs glucose metabolism by raising intracellular mannose-6-phosphate levels. Such alterations result in the suppression of succinate-mediated HIF-1α activation, imposing a consequent reduction of LPS-induced Il1b expression. Disclosing an unrecognized metabolic hijack of macrophage activation, our study points towards safe D-mannose utilization as an effective intervention against inflammatory conditions.

20 December 2010 in Haematologica
Verified
Journal Article
Closed access
TBT. Barbui
T. Barbui
ACA. Carobbio
A. Carobbio
GFG. Finazzi
G. Finazzi
AVA. M. Vannucchi
A. M. Vannucchi
GBG. Barosi
G. Barosi
OIon behalf of the AGIMM and IIC Investigators
on behalf of the AGIMM and IIC Investigators
We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera. High sensitivity C-reactive protein and pentraxin 3 were measured in 244 consecutive essential thrombocythemia and polycythemia vera patients in whom, after a median follow up of 5.3 years (range 0-24), 68 cardiovascular events were diagnosed. The highest C-reactive protein tertile was compared with the lowest (>3 vs. <1 mg/L) and correlated with age (P=0.001), phenotype (polycythemia vera vs. essential thrombocythemia, P=0.006), cardiovascular risk factors (P=0.012) and JAK2V617F allele burden greater than 50% (P=0.003). Major thrombosis rate was higher in the highest C-reactive protein tertile (P=0.01) and lower at the highest pentraxin 3 levels (P=0.045). These associations remained significant in multivariate analyses and indicate that blood levels of high sensitivity C-reactive protein and petraxin 3 independently and in opposite ways modulate the intrinsic risk of cardiovascular events in patients with myeloproliferative disorders.

25 January 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FFFabio Fiordaliso
Fabio Fiordaliso
SCStefano Chimenti
Stefano Chimenti
LSLidia Staszewsky
Lidia Staszewsky
ABAntonio Bai
Antonio Bai
ECEleonora Carlo
Eleonora Carlo
RLRoberto Latini
Roberto Latini
The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by preventing apoptosis. However, EPO administration can also raise the hemoglobin concentration, which, by increasing oxygen delivery, confounds assignment of cause and effect. The availability of EPO analogs that do not bind to the dimeric EPO receptor and lack erythropoietic activity, e.g., carbamylated EPO (CEPO), provides an opportunity to determine whether EPO possesses direct cardioprotective activity. In vivo , cardiomyocyte loss after experimental myocardial infarction (MI) of rats (40 min of occlusion with reperfusion) was reduced from ≈57% in MI-control to ≈45% in animals that were administered CEPO daily for 1 week (50 μg/kg of body weight s.c.) with the first dose administered intravenously 5 min before reperfusion. CEPO did not increase the hematocrit, yet it prevented increases in left ventricular (LV) end-diastolic pressure, reduced LV wall stress in systole and diastole, and improved LV response to dobutamine infusion compared with vehicle-treated animals. In agreement with the cardioprotective effect observed in vivo , staurosporine-induced apoptosis of adult rat or mouse cardiomyocytes in vitro was also significantly attenuated (≈35%) by CEPO, which is comparable with the effect of EPO. These data indicate that prevention of cardiomyocyte apoptosis, in the absence of an increase in hemoglobin concentration, explains EPO's cardioprotection. Nonerythropoietic derivatives such as CEPO, devoid of the undesirable effects of EPO, e.g., thrombogenesis, could represent safer and more effective alternatives for treatment of cardiovascular diseases, such as MI and heart failure. Furthermore, these findings expand the activity spectrum of CEPO to tissues outside the nervous system.

1 November 2004 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
FFFabio Fiordaliso
Fabio Fiordaliso
RBRoberto Bianchi
Roberto Bianchi
LSLidia Staszewsky
Lidia Staszewsky
ICIvan Cuccovillo
Ivan Cuccovillo
MDMirko Doni
Mirko Doni
RLRoberto Latini
Roberto Latini

30 January 2010 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
TMTommaso Mauri
Tommaso Mauri
GBGiacomo Bellani
Giacomo Bellani
NPNicolò Patroniti
Nicolò Patroniti
ACAndrea Coppadoro
Andrea Coppadoro
GPGiuseppe Peri
Giuseppe Peri
Alberto MantovaniAlberto Mantovani
Alberto Mantovani